Filing Analysis
Solesence, Inc. filed an 8-K to announce its results of operations and financial condition via a press release and earnings call transcript. The filing serves as a standard mechanism to communicate quarterly or annual financial performance to the market.
📋 Key Facts
- The company issued a press release on August 19, 2026, regarding results of operations and financial condition.
- An earnings call transcript was provided as an exhibit.
- The filing was signed by CFO Laura Riffner.
Solésence, Inc. entered into a Settlement Agreement with Refy Beauty Ltd to resolve disputes regarding previous consumer care product sales. The company will pay approximately $938,000 in twelve monthly installments and has established an exclusivity period for potential new SPF product development.
🚩 Red Flags
- Legal dispute settlement indicates past friction in commercial relationships/product quality issues.
- Cash outflow of nearly $1M over the next year for non-operating settlement purposes.
📋 Key Facts
- Settlement amount: British Pound Sterling equivalent of $938,000.
- Payment structure: 12 equal installments of $78,166.66 starting August 5, 2026.
- Parties involved: Solésence, LLC (subsidiary) and Refy Beauty Ltd.
- Includes a six-month exclusivity period for SPF product development.
- Potential credit mechanism: Final 6 installments may be credited toward future SPF product purchases if a supply agreement is reached.
Solesence, Inc. filed a Form 8-K on May 12, 2026, to announce its results of operations and financial condition. The filing includes a press release as Exhibit 99.1, which is standard for quarterly or annual earnings announcements.
📋 Key Facts
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release dated May 12, 2026, was included as Exhibit 99.1.
- The document was signed by Chief Financial Officer Laura Riffner.
- The company is listed on the NASDAQ Capital Market under the ticker symbol SLSN.
Solesence, Inc. has appointed Marc James to its Board of Directors as a Class II Director, effective April 24, 2026. Mr. James will serve on the Audit and Finance, Compensation, and Nominating and Corporate Governance committees.
📋 Key Facts
- Marc James was appointed as a Class II Director effective April 24, 2026.
- The term for this position expires at the 2026 Annual Meeting of Shareholders.
- Mr. James was appointed to three committees: Audit and Finance, Compensation, and Nominating and Corporate Governance.
- The filing was signed by CFO Laura Riffner on April 28, 2026.
Solesence, Inc. filed an 8-K on March 31, 2026, to report its results of operations and financial condition via a press release. This is a routine disclosure of financial performance for the period ending March 31, 2026.
📋 Key Facts
- The filing was made under Item 2.02: Results of Operations and Financial Condition.
- A press release dated March 31, 2026, was included as Exhibit 99.1.
- The report was signed by Laura Riffner, Chief Financial Officer.
- The company is incorporated in Delaware and listed on The NASDAQ Capital Market under the symbol SLSN.
Solesence, Inc. has finalized a separation agreement with former CEO Jess Jankowski following his resignation. The agreement includes significant severance payments and accelerated option vesting.
🚩 Red Flags
- Significant cash outflow via severance ($366,912) and accelerated equity vesting in a micro-cap context.
- Leadership instability following the departure of the CEO.
📋 Key Facts
- Former CEO Jess Jankowski resigned as an officer of the Company.
- Separation Agreement effective date: December 2, 2025.
- Total gross severance pay amount: $366,912.
- Agreement includes accelerated vesting of all outstanding options for Mr. Jankowski.
- Company will pay monthly COBRA insurance premiums during the severance period.
Solesence, Inc. announced the retirement and resignation of Jess Jankowski from the Board of Directors effective November 21, 2025. Following his departure, the company entered into a consulting agreement with Mr. Jankowski to assist with management, financial records, and SEC filings.
🚩 Red Flags
- Departure of a key executive (former CEO/CFO) often signals transition or internal shifts, though here it is framed as retirement.
- The specific focus of the consulting agreement on 'financial records and SEC filings' may suggest a need for transitional support in financial reporting following the CFO's departure.
📋 Key Facts
- Jess Jankowski retired as CEO/CFO and resigned from the Board on November 21, 2025.
- The Company entered into a Consulting Agreement with Mr. Jankowski effective November 22, 2025.
- Consulting services include management, financial records, SEC filings, and related matters.
- Consulting fee is set at $177 per hour for up to 80 hours of service.
- Kevin Cureton (CEO and President) was appointed to fill Mr. Jankowski's Class III Director seat.
Solésence, Inc. filed an 8-K to announce its third quarter 2025 results and provide a conference call script. The filing serves as a formal announcement of quarterly financial performance.
📋 Key Facts
- Report date: November 11, 2025
- The company issued a press release regarding Q3 2025 results (Exhibit 99.1).
- Included the Third Quarter 2025 Conference Call Script as Exhibit 99.2.
Solésence, Inc. entered into a Confidential Settlement Agreement with Solarium Brands, LLC and A-Frame Brands, LLC to resolve disputes regarding consumer care products. The settlement includes a one-time payment of $675,000 due by January 15, 2026.
🚩 Red Flags
- Legal dispute resolution (indicates past friction with a customer/partner).
📋 Key Facts
- Settlement Agreement entered into on October 31, 2025.
- Parties involved: Solésence, Inc. (and subsidiary Solésence, LLC) and Solarium Brands, LLC / A-Frame Brands, LLC.
- Subject matter: Disputes relating to certain consumer care products previously sold by Solésence to Solarium.
- Settlement amount: $675,000 one-time payment.
- Payment deadline: On or before January 15, 2026.
Solésence, Inc. announced a significant leadership overhaul effective September 3, 2025, involving the appointment of a new CEO and CFO alongside the transition/retirement of the outgoing CEO.
🚩 Red Flags
- Management turnover: Simultaneous change in CEO and CFO positions can indicate internal instability or strategic shifts.
- Succession risk: The outgoing CEO is transitioning to an advisory role rather than immediate departure, which may overlap responsibilities during the transition period.
📋 Key Facts
- Kevin Cureton (age 64) appointed as Chief Executive Officer and President; previously COO since 2019. Base salary: ≥$367,000 plus bonuses/options.
- Laura Riffner appointed as Chief Financial Officer; formerly CFO at Nagase America and Paxton/Patterson. Base salary: ≥$270,000 plus bonuses/options.
- Jess Jankowski (outgoing CEO/CFO) will serve as Board Advisor until his retirement on November 21, 2025. Base salary through retirement: $366,912.00.
Solésence, Inc. held its Annual Meeting of Shareholders on August 28, 2025. The meeting resulted in the election of two directors, approval of a new equity compensation plan, and ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on August 28, 2025.
- Quorum was established with 61,205,907 shares (86.83% of outstanding shares) present or represented by proxy.
- R. Janet Whitmore and Laura M. Beres were elected to the Board of Directors.
- The 2025 Equity Compensation Plan was approved by shareholders.
- RSM US LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
Solesence, Inc. filed an 8-K to announce the release of a press statement regarding its results of operations and financial condition as of July 31, 2025.
📋 Key Facts
- The filing is associated with Item 2.02 (Results of Operations and Financial Condition).
- A press release was issued on July 31, 2025, which is incorporated by reference as Exhibit 99.1.
- The company is listed on the NASDAQ Capital Market under the ticker SLSN.
The company filed a Certificate of Correction to its previously filed Amendment to the Certificate of Incorporation. This filing is purely administrative, intended to add an accent over the first 'e' in the company's name (changing Solesence, Inc. to Solésence, Inc.).
📋 Key Facts
- Filed a Certificate of Correction on June 3, 2025.
- The correction addresses an inadvertent omission of an accent over the first 'e' in the company name.
- No other changes were made to the previously filed Amendment from March 10, 2025.
- Company name changed from Nanophase Technologies Corporation to Solésence, Inc.
Solésence, Inc. entered into three loan amendments with entities affiliated with its controlling shareholder, Bradford T. Whitmore. These amendments increase borrowing capacities and extend maturity dates from October 2025 to April 2027.
🚩 Red Flags
- Related-party transactions: The loans are provided by entities controlled by the company's controlling shareholder.
- Liquidity pressure: Extension of maturity dates suggests a need for more time to meet debt obligations, though it provides breathing room until 2027.
- Increased leverage: Significant increase in maximum borrowing capacity increases the total debt burden on the company.
📋 Key Facts
- Entered into three loan amendments on May 27, 2025: Term Loan Agreement Amendment, A/R Loan Agreement Amendment, and Revolving Loan Agreement Amendment.
- Revolving Loan capacity increased from $5.2 million to $10.0 million.
- A/R Loan capacity increased from $8.0 million to $12.0 million.
- Maturity dates for all three loans extended from October 1, 2025, to April 30, 2027.
- Loan counterparties (Strandler, LLC and Beachcorp, LLC) are affiliates of controlling shareholder Bradford T. Whitmore.
Solésence, Inc. filed an 8-K to announce the release of its first quarter 2025 financial results and a corresponding conference call script.
📋 Key Facts
- Report date: May 5, 2025
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Q1 2025 Conference Call Script).
- The company is reporting results of operations and financial condition for the first quarter of 2025.
Solesence, Inc. announced its uplisting to the NASDAQ Stock Market and a restructuring of its Audit and Finance Committee. The filing includes the appointment of Laura Beres as Chair and Mark Miller as a new member of the committee.
📋 Key Facts
- Company is uplisting to The NASDAQ Stock Market LLC.
- The Board of Directors replaced the existing members of the Audit and Finance Committee on April 4, 2025.
- New Audit and Finance Committee composition: Laura Beres (Chair) and Mark Miller.
The company filed an 8-K to announce the issuance of a press release regarding its results of operations and financial condition. The filing itself contains no specific financial data, deferring all details to Exhibit 99.1.
🚩 Red Flags
- Lack of substantive data in the 8-K itself; all material information is contained in the attached press release which must be reviewed separately.
📋 Key Facts
- Filing date: March 26, 2025
- The report is filed under Item 2.02 (Results of Operations and Financial Condition)
- A press release was issued on the same date (March 26, 2025) as Exhibit 99.1
Nanophase Technologies Corporation has officially changed its corporate name to 'Solesence, Inc.' via a Certificate of Amendment filed in Delaware. This change is part of a rebranding strategy focused on the company's beauty science platform.
📋 Key Facts
- Effective date of name change: March 10, 2025
- New corporate name: Solescence, Inc.
- Reason for change: Rebranding to emphasize success in the beauty science and skin health sector
- Filed with the Secretary of State of Delaware
Nanophase Technologies Corporation shareholders approved an amendment to the Certificate of Incorporation to increase authorized common stock from 60,000,000 to 95,000,000 shares. The amendment became effective on June 19, 2024.
🚩 Red Flags
- Significant increase in authorized share count (58.3% increase) often precedes dilutive equity offerings to raise capital.
📋 Key Facts
- Shareholders approved the increase of authorized common stock at a Special Meeting held on June 18, 2024.
- Authorized shares increased from 60,000,000 to 95,000,000.
- The amendment was filed with the Secretary of State of Delaware on June 19, 2024.
- Quorum was met with approximately 76% (41,899,684 shares) of entitled shares represented at the meeting.
Nanophase Technologies Corporation held its Annual Meeting of Shareholders on December 18, 2024. The meeting resulted in the election of two directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on December 18, 2024.
- Quorum was established with 54,315,518 shares (77.6% of outstanding shares) present or represented by proxy.
- Jess A. Jankowski elected to the Board of Directors with 54,280,750 votes in favor.
- Mark E. Miller elected to the Board of Directors with 54,300,526 votes in favor.
- Ratification of RSM US LLP as independent registered public accounting firm for fiscal year 2024 was approved by shareholders.
Nanophase Technologies Corporation filed an 8-K to announce the release of its quarterly results or other financial updates via a press release. The filing itself contains no specific financial data, only referencing Exhibit 99.1.
📋 Key Facts
- Filing date: October 30, 2024
- The company issued a press release regarding Results of Operations and Financial Condition (Item 2.02)
- The filing is an announcement of the availability of financial results rather than a detailed disclosure itself.
Nanophase Technologies Corporation filed an 8-K to announce the issuance of a press release regarding its results of operations and financial condition for the period ending August 6, 2024.
📋 Key Facts
- The filing is primarily used to incorporate Exhibit 99.1 (Press Release) by reference.
- The report relates to Item 2.02: Results of Operations and Financial Condition.
- Report date: August 6, 2024.
Nanophase Technologies Corporation filed an 8-K to announce the release of its quarterly results via a press release. The filing itself contains no specific financial data or material changes, acting only as a placeholder for Exhibit 99.1.
📋 Key Facts
- The company issued a press release on April 23, 2024, regarding Results of Operations and Financial Condition (Item 2.02).
- The filing is a standard announcement of quarterly financial results.
Nanophase Technologies Corporation has entered into a Settlement Agreement and Amendment No. 5 to its Zinc Oxide Supply Agreement with BASF Corporation, resolving long-standing litigation regarding exclusivity breaches. The settlement includes a new Memorandum of Understanding for the development of modified zinc oxide products for BASF's exclusive purchase.
🚩 Red Flags
- Resolution of litigation involving allegations of breach of exclusivity (historical risk).
📋 Key Facts
- Settlement reached on April 10, 2024, to resolve New Jersey Litigation (BASF Corp. v. Nanophase Technologies Corp.).
- Amendment No. 5 grants BASF exclusive rights to zinc oxide materials developed/sold by Nanophase for specific designated uses ('the Field').
- Nanophase and its subsidiary Solésence, LLC retain the right to sell certain finished products and dispersions containing zinc oxide to other customers.
- The parties entered into a 'Modified Product MOU' regarding the development of new zinc oxide products for BASF's exclusive use.
- The settlement includes a mutual release of all claims related to the New Jersey Litigation.
Nanophase Technologies Corporation filed an 8-K to announce the release of a press statement regarding its results of operations and financial condition. The filing serves as a placeholder for the attached Exhibit 99.1.
📋 Key Facts
- The report was filed on March 20, 2024.
- The company issued a press release (Exhibit 99.1) regarding results of operations and financial condition.
- The filing is categorized under Item 2.02: Results of Operations and Financial Condition.
Nanophase Technologies entered into a $6 million securities purchase agreement with Strandler, LLC, an affiliate of the company's controlling shareholder. The deal involves highly dilutive Series X Preferred Stock and significant restrictive covenants.
🚩 Red Flags
- Related-party transaction: The primary investor is an affiliate of the controlling shareholder.
- Extreme Dilution Risk: Conversion ratio is 1,000 common shares for every 1 preferred share (a massive multiplier).
- Liquidation Preference/Redemption: Preferred stock has a $400 liquidation preference and a $420 redemption option if certain conditions aren't met.
- Restrictive Covenants: The company is prohibited from paying dividends or repurchasing stock, and faces restrictions on asset liens.
📋 Key Facts
- Issued 15,000 shares of Series X Preferred Stock to Strandler, LLC for $6,000,000 ($400 per share).
- Strandler, LLC is an affiliate of controlling shareholder Bradford T. Whitmore.
- Series X Preferred Stock converts into 1,000 shares of Common Stock per preferred share upon a specific certificate amendment.
- If the company fails to amend its charter by August 1, 2024, Strandler has the option to redeem shares at $420 per share.
- The agreement includes restrictive covenants preventing dividends, repurchases, and certain encumbrances on assets.
- Maturity dates for existing loans with Strandler and Beachcorp (affiliate of Whitmore) were extended from March 31, 2025, to October 1, 2025.